Telomerase inhibitor imetelstat in essential thrombocythemia and myelofibrosis

New England Journal of Medicine

Volumn 373, Issue 26, 2015, Pages 2579-2581

  El Fassi, Daniel ^a   Bjørn, Mads E ^b   Nielsen, Claus H ^c   Hasselbalch, Hans C ^b   Baerlocher, Gabriela M ^d   Burington, Bart ^e   Snyder, David S ^f   Tefferi, Ayalew ^g  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

^c Institute for Inflammation Research   (Denmark)

^d UNIVERSITY OF BERN   (Switzerland)

^e Geron   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMETELSTAT; JANUS KINASE 2; PEGINTERFERON ALPHA2B; INDOLE DERIVATIVE; NICOTINAMIDE; TELOMERASE;

DIARRHEA; DISEASE COURSE; FATIGUE; HUMAN; LETTER; MYELOFIBROSIS; NAUSEA; PRIORITY JOURNAL; REMISSION; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; THROMBOCYTHEMIA, ESSENTIAL; PRIMARY MYELOFIBROSIS;

FEMALE; HUMANS; INDOLES; MALE; NIACINAMIDE; TELOMERASE; THROMBOCYTHEMIA, ESSENTIAL; PRIMARY MYELOFIBROSIS;

EID: 84951967364     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1512663     Document Type: Letter

References (14)

1. Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med 2015; 373: 920-8.
2. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761-70.
3. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 2013; 6: 49-58.
4. Larsen TS, Møller MB, de Stricker K, et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera: a report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009; 14: 331-4.
5. El Fassi D, Andersen CL, Larsen TS, et al. National clinical guideline for treatment of essential thrombocythemia. December 2014 (http://www.myeloid.dk/filearchive/eff662fd2cd3f3f341e32c8bdb6e817a.pdf).
6. Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 2015; 373: 908-19.
7. Armanios M, Greider CW. Treating myeloproliferation - on target or off? N Engl J Med 2015; 373: 965-6.
8. Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective. Toxicol Pathol 2015; 43: 78-89.
9. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 2013; 6: 49-58.
10. Utke Rank C, Weis Bjerrum O, Larsen TS, et al. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma 2015 June 18 (Epub ahead of print).
11. Xu D, Erickson S, Szeps M, et al. Interferon alpha downregulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 2000; 96: 4313-8.
12. Cassinat B, Verger E, Kiladjian JJ. Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med 2014; 371: 188-9.
13. Kuriakose ET, Gjoni S, Wang YL, et al. JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. Haematologica 2013; 98(11): e135-7.
14. Kiladjian JJ, Massé A, Cassinat B, et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha- 2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia 2010; 24: 1519-23.